Source comparison
Melanotan-2 SubQ vs IM: Route Comparison
Time to Peak Plasma Concentration (Tmax) 12–18 hours 2–4 hours Determines when melanocortin receptor activation peaks SubQ delays onset; IM accelerates it Nausea Incidence 15–25% of injections 40–60% of injections MC4R activation in area postrema scales with c
This comparison does not assign a generated winner or score.
- Time to Peak Plasma Concentration (Tmax)
- 12–18 hours
- 2–4 hours
- Determines when melanocortin receptor activation peaks
- SubQ delays onset; IM accelerates it
- Nausea Incidence
- 15–25% of injections
- 40–60% of injections
- MC4R activation in area postrema scales with concentration rate
- SubQ reduces acute GI side effects
- Facial Flushing Intensity
- Mild, transient (30% incidence)
- Pronounced, sustained (60–70% incidence)
- Alpha-MSH-mediated vasodilation correlates with Cmax slope
- IM amplifies vascular response
- Needle Specification
- 27–30 gauge, 5–8mm length
- 23–25 gauge, 1–1.5 inch length
- Tissue penetration depth determines kinetic profile
- Match gauge to target tissue
- Injection Site Rotation Requirement
- Moderate (every 3–5 injections)
- High (every injection to prevent fibrosis)
- Repeated IM at same site causes scar tissue buildup
- IM demands stricter rotation
- Suitable for Multi-Week Protocols
- Yes. Sustained release minimises symptom spikes
- Tolerable but side effects accumulate
- Chronic IM intensifies receptor desensitisation fatigue
- SubQ preferred for extended use